DELEK GROUP
HEADQUARTERS
- 19 Abba Eban Blvd.
- POB 2054 Herzlia 4612001 Israel
- Tel: +972 9 863 8444
- Fax: +972 9 885 4955
- Email: [email protected]
As a consequence of Delek Group Ltd.’s (“Delek”) anticipated shareholding following completion of the proposed combination between Capricorn Energy PLC (“Capricorn“) and NewMed Energy Limited Partnership (“NewMed“) (the “Recommended Combination”), the Recommended Combination is conditional on a Rule 9 waiver from the UK Takeover Panel in order to disapply mandatory offer requirements pursuant to Rule 9 of the UK City Code on Takeovers and Mergers (the “Rule 9 Waiver”).
Access to the Information
You are attempting to enter the part of the website that is designated for the publication of documents and information in connection with the Recommended Combination and the Rule 9 Waiver. The materials you are seeking to access are made available in good faith and for informational purposes only and are subject to the terms and conditions set out below. Any person seeking access to this part of Delek’s website represents and warrants to Delek that they are doing so for informational purposes only. Making the information available in electronic format is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Recommended Combination or the Rule 9 Waiver.
If you would like to view this part of the website, please read this notice carefully. This notice applies to all persons who view this part of the website and, depending on where you are located, may affect your rights or responsibilities. Delek reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit the site. In addition, the contents of this part of the website may be amended at any time, in whole or in part, at the sole discretion of Delek.
Overseas jurisdictions
Viewing the materials you are seeking to access may be restricted under securities laws in certain jurisdictions. In certain jurisdictions, only certain categories of persons may be allowed to view such materials. All persons who wish to view the information contained in this part of the website must first satisfy themselves that they are not subject to any local requirements which prohibit or restrict them from doing so and should inform themselves about, and observe, any legal or regulatory requirements applicable in their jurisdiction.
The materials contained in this part of the website are not directed at or intended to be accessible by persons resident in any jurisdiction if to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.
YOU SHOULD NOT DOWNLOAD, MAIL, FORWARD, DISTRIBUTE, SEND OR SHARE THE INFORMATION OR DOCUMENTS CONTAINED ON THIS MICROSITE TO ANY PERSON. IN PARTICULAR, YOU SHOULD NOT MAIL, FORWARD, DISTRIBUTE OR SEND THE INFORMATION OR DOCUMENTS CONTAINED THEREIN TO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL TO DO SO.
This part of the website contains information that has been prepared for the purposes of complying with the UK City Code on Takeovers and Mergers and the information disclosed may not be the same as that which would have been disclosed if this information had been prepared in accordance with the laws and regulations of any jurisdiction outside of England and Wales.
It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should not continue to seek to access this part of the website.
Responsibility
In relation to any materials related to the Recommended Combination that are accessible on this part of the website, please note any statement of responsibility contained therein.
Confirmation of understanding and acceptance
If you are unable to agree, you should click “I DECLINE” and you will not be able to view information about the Recommended Combination and the Rule 9 Waiver.
